Australia's most trusted
source of pharma news
Saturday, 10 May 2025
Posted 6 May 2025 AM
Eli Lilly's challenger to Sanofi's blockbuster Dupixent is back in action, with Lilly making the next move in getting its IL-13 inhibitor listed on the PBS.
Ebglyss was the second drug mentioned by Clarivate in March on its 'list of drugs to watch', as it is predicted to earn US$6 billion from the G7 countries in 2030.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.